Rocket Aborts FDA Filing for Rare Blood Disease Gene Therapy
Rocket Pharmaceuticals’ strategic realignment initiative in July pulled funding from fanca-cel, which the biotech was developing for Fanconi anemia.
Rocket Aborts FDA Filing for Rare Blood Disease Gene Therapy Read More »
